Spongipregnoloside A



Compound IDCDAMM01598
Common nameSpongipregnoloside A
IUPAC name1-[3-[4,5-dihydroxy-6-(hydroxymethyl)-3-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxy-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15-decahydro-1H-cyclopenta[a]phenanthren-17-yl]ethanone
Molecular formulaC33H50O11

Experimental data

Retention time14.03
Adduct[M+H]+
Actual mz623.342
Theoretical mz623.342
Error1.08
Ionizaton modePositive
Instrument typeLC-MS/MS-QTOF, spectrum predicted by MS-DIAL v4.9 integrated with MS-FINDER 3.60
Score6.8717

Identifiers and class information

Inchi keyBXARCUHDNQOUJG-BQTXKVTDNA-N
SmilesO=C(C1=CCC2C3CC=C4CC(OC5OC(CO)C(O)C(O)C5OC6OC(C)C(O)C(O)C6O)CCC4(C)C3CCC12C)C
SuperclassLipids and lipid-like molecules
ClassSteroids and steroid derivatives

Pharmacokinetic properties

Number of descriptor values(#stars)2
Number of non-conjugated amine groups (#amine)0
Number of amidine and guanidine groups (#amidine)0
Number of carboxylic acid groups (#acid)0
Number of non-conjugated amide groups (#amide)0
Number of rotatable bonds (#rotor)12
Number of reactive functional groups (#rtvFG)2
Predicted central nervous system activity (CNS)-2
Molecular weight (mol_MW)622.751
Computed dipole moment(dipole)7.164
Total solvent accessible surface area (SASA)846.035
Hydrophobic component of SASA (FOSA)563.006
Hydrophilic component of SASA (FISA)231.106
Pie component of the SASA (PISA)51.922
Weakly polar component of the SASA (WPSA)0
Total solvent accesible volume (volume)1748.34
Number of hydrogen bond donors (donorHB)6
Number of hydrogen bond acceptors (accptHB)19
Free energy of solvation of dipole (dip^2/V)0.0293526
Index of cohesive interaction in solids (ACxDN^.5/SA)0.0550099
Globularity descriptor (glob)0.829586
Predicted polarizability in cubic angstroms (QPpolrz)56.605
Predicted hexadecane/gas partition coefficient (QPlogPC16)17.492
Predicted octanol/gas partition coefficient (QPlogPoct)38.591
Predicted water/gas partition coefficient (QPlogPw)28.536
Predicted octanol/water partition coefficient (QPlogPo/w)0.55
Predicted aqueous solubility (QPlogS)-3.437
Conformation-independent predicted aqueous solubility (CIQPlogS)-4.331
Predicted IC50 value for blockage of HERG K+ channels (QPlogHERG)-4.537
Predicted apparent Caco-2 cell permeability in nm/sec (QPPCaco)63.726
Predicted brain/blood partition coefficient (QPlogBB)-2.398
Predicted apparent MDCK cell permeability in nm/sec (QPPMDCK)25.232
Predicted skin permeability, log Kp (QPlogKp)-4.444
PM3 calculated ionization potential (IP(ev))9.393
PM3 calculated electron affinity (EA(eV))0.146
Number of likely metabolic reactions (#metab)9
Prediction of binding to human serum albumin (QPlogKhsa)-0.621
Predicted qualitative human oral absorption (HumanOralAbsorption)2
Predicted human oral absorption on 0 to 100% scale (PercentHumanOralAbsorption)23.587
Solvent-accessible surface area of fluorine atoms (SAFluorine)0
Solvent-accessible surface area of amide oxygen atoms (SAamideO)0
Van der Waals surface area (PSA)179.27
Number of nitrogen and oxygen atoms (#NandO)11
Number of violations of Lipinski’s rule of five (RuleOfFive)3
Number of violations of Jorgensen’s rule of three (RuleOfThree)1

Compound-target network

Cytoscape Graph

Protein targets associated with phytocompound

Uniprot ID Gene name Target name TTD_ID Prediction source
P31213SRD5A2Steroid 5-alpha-reductase 2T71390SEA
P08185SERPINA6Corticosteroid binding globulinT88452SEA
Q9UHC9NPC1L1Niemann-Pick C1-like protein 1T33901SEA
Q13133NR1H3LXR-alphaT52297SEA
P11413G6PDGlucose-6-phosphate 1-dehydrogenaseT63484SEA
P05093CYP17A1Cytochrome P450 17A1T89041SEA
P15692VEGFAVascular endothelial growth factor AT20761SEA
P05230FGF1Acidic fibroblast growth factorT18639SEA
P09038FGF2Basic fibroblast growth factorT31621SEA
P60568IL2Interleukin-2T61698SEA
P17931LGALS3Galectin-3T72038SEA
P04746AMY2APancreatic alpha-amylaseT86918SEA
P14679TYRTyrosinaseT97035SEA
Q99417MYCBPMYCBP messenger RNAT37298SEA
O15439ABCC4Multidrug resistance protein 4T39919SEA

Target associated diseases

TTD_ID Disease_ID Disease name ICD_11 Uniprot ID Gene names
T71390DI0348Prostate hyperplasia[ICD-11: GA90]P31213SRD5A2
T88452DI0037Asthma[ICD-11: CA23]P08185SERPINA6
T88452DI0339Postoperative inflammation[ICD-11: 1A00-CA43]P08185SERPINA6
T88452DI0362Respiratory system disease[ICD-11: CB40-CB7Z]P08185SERPINA6
T33901DI0188Hyper-lipoproteinaemia[ICD-11: 5C80]Q9UHC9NPC1L1
T52297DI0117Depression[ICD-11: 6A70-6A7Z]Q13133NR1H3
T63484DI0086Chronic obstructive pulmonary disease[ICD-11: CA22]P11413G6PD
T89041DI0346Prostate cancer[ICD-11: 2C82]P05093CYP17A1
T20761DI0095Colorectal cancer[ICD-11: 2B91]P15692VEGFA
T20761DI0365Retinopathy[ICD-11: 9B71]P15692VEGFA
T20761DI0430Vascular system developmental anomaly[ICD-11: LA90]P15692VEGFA
T18639DI0081Chronic arterial occlusive disease[ICD-11: BD4Z]P05230FGF1
T18639DI0102Coronary atherosclerosis[ICD-11: BA52]P05230FGF1
T31621DI0005Acne vulgaris[ICD-11: ED80]P09038FGF2
T61698DI0275Multiple sclerosis[ICD-11: 8A40]P60568IL2
T61698DI0361Renal cell carcinoma[ICD-11: 2C90]P60568IL2
T72038DI0190Hypertension[ICD-11: BA00-BA04]P17931LGALS3
T72038DI0199Idiopathic interstitial pneumonitis[ICD-11: CB03]P17931LGALS3
T72038DI0252Melanoma[ICD-11: 2C30]P17931LGALS3
T72038DI0302Non-alcoholic fatty liver disease[ICD-11: DB92]P17931LGALS3
T72038DI0351Psoriasis[ICD-11: EA90]P17931LGALS3
T86918DI0110Cystic fibrosis[ICD-11: CA25]P04746AMY2A
T86918DI0328Pancreatic malfunction[ICD-11: DC30-DC3Z]P04746AMY2A
T97035DI0007Acquired hypermelanosis[ICD-11: ED60]P14679TYR
T97035DI0008Acquired hypomelanotic disorder[ICD-11: ED63]P14679TYR
T37298DI0235Liver cancer[ICD-11: 2C12]Q99417MYCBP

Copyright © 2025